Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | AMY2A | P04746 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709746 | 0.90 | LGALS8 (0.33) | LGALS8AMY2AOGA | |
| SCHEMBL17058711 | 0.90 | LGALS8 (0.33) | LGALS8AMY2AOGA | |
| SCHEMBL24709744 | 0.90 | LGALS8 (0.33) | LGALS8AMY2AOGA | |
| SCHEMBL23378918 | 0.90 | LGALS8 (0.33) | LGALS8AMY2AOGA | |
| SCHEMBL13864486 | 0.90 | LGALS8 (0.33) | LGALS8AMY2AOGA | |
| SCHEMBL18868622 | 0.80 | AMY1A (0.38) | LGALS8 | |
| SCHEMBL13625826 | 0.79 | — | — | |
| SCHEMBL20845380 | 0.78 | L3MBTL1 (0.31) | — | |
| SCHEMBL12899675 | 0.78 | LGALS8 (0.45) | LGALS8OGA | |
| SCHEMBL12141264 | 0.78 | LGALS8 (0.45) | LGALS8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145852-A1 | Combination Therapies for Treating Muscular Dystrophy | SAREPTA THERAPEUTICS INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210102205-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-9517977-B2 | Materials for electronic devices | MERCK PATENT GMBH (DE) | 2016-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145852-A1 | Combination Therapies for Treating Muscular Dystrophy | UTRN, MBNL1, TNNC1 | LGALS8 1101/4885AMY2A 3161/4885OGA 4276/4885 |
| US-20210102205-A1 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, RBM17, UPF1 | LGALS8 2500/4885AMY2A 2961/4885OGA 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.